4. Safe Harbor Statement
• This presentation may contain “forward-looking statements” as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on current expectations of future
events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize,
actual results could vary materially from the Company’s expectations and projections.
• Risks and uncertainties include general industry conditions and competition; economic conditions,
such as interest rate and currency exchange rate fluctuations; technological advances and patents
attained by competitors; challenges inherent in new product development, including obtaining
regulatory approvals; domestic and foreign health care reforms and governmental laws and
regulations; and trends toward health care cost containment.
• A further list and description of these risks, uncertainties and other factors can be found
in Exhibit 99 to the Company’s Annual Report on Form 10-K for the fiscal year ended
December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online
at www.sec.gov, www.jnj.com, or on request from the Company. The Company does not undertake
to update any forward-looking statements as a result of new information or future events or
developments.
8. Alex Gorsky
Worldwide Chairman
Medical Devices & Diagnostics
9.
10. WW Medical Devices & Diagnostics Market – $335B
MD&D Market Segments* Segment Value 2008-12
(US $ in Billions) CAGR
Total 2008 WW MD&D Market Blue = Where J&J MD&D Competes
Surgical Instrument / Other 47 7.4 %
Imaging 42 2.9 %
Cardiovascular 32 6.9 %
In‐Vitros Diagnostics 30 7.4 %
Orthopaedics 27 8.1 %
Vision 20 6.3 %
$157B
US Dental 18 3.5 %
$178B 47% Urology & Renal
Wound Care
15
12
5.6 %
6.9 %
OUS 53%
Endoscopy 11 7.0 %
Drug Delivery 10 6.8 %
Energy‐Based/Radiotherapy 10 6.9 %
Diabetes SMBG & Int. Sol 9 7.0 %
Critical Care 7 3.7 %
Opthalmic Surgery 6 6.3 %
Sports Medicine 4 9.5 %
Blood Donation & Proc. 3 5.3 %
Overall MD&D Market CAGR (2008-12) 6.5% Neuromodulation 3 16.0 %
Infection Control 3 6.0 %
Aesthetics 2 21.6 %
Neurosurgery/ICU/Instruments 2 3.1 %
*Market Segments listed above do not include certain minor categories such as Insulin Delivery – Pumps 1 15.2 %
Patients Aids & Home, Non Electrical Diagnostics and other minor markets
Source: HRI, Internal Estimates
11. Largest MD&D Business in the World
• Strong track record of financial performance
• Leadership positions (#1 or #2) in key segments
• Compete in attractive categories
• Global capabilities and advantages of scale
• Unique understanding of chronic disease states
• Depth and breadth of Johnson & Johnson
14. Key Growth Strategies
• Grow core businesses
• Launch breakthrough new products/technologies
• Accelerate growth in emerging markets
• Drive operational effectiveness and efficiency
15. Key Growth Strategies:
Grow Core Businesses
Joint Contact Clinical
Sutures Reconstruction SMBG Lenses Labs
WW Market $3.1B $13.2B $8.5B $5.7B $13.3B
J&J WW
Market Position #1 #2 #2 #1 #5
J&J WW 75% 20% 27% 45% 7%
$ Market Share
Source: Combination of external and internal estimates. WW Market data reflect 2009 estimates; WW Market Position and Market Share
data reflect YE’08 actuals.
16. Sutures:
Coated VICRYL™ Plus Antibacterial Suture
• Faster, event-free closure
• First and only suture
of its kind
• Protects against
bacterial colonization
• Tiered strategy for developed
vs. emerging markets
17. Joint Reconstruction:
Pinnacle® CoMplete Acetabular Cup System
• First ceramic-on-metal hip bearing considered by FDA
• Combines durability/stability of metal-on-metal bearings with
enhanced wear characteristics of ceramic-on-ceramic bearings
• Laboratory testing showed:
– >90% wear reduction compared to metal-on-metal under normal
gait conditions
– 80% reduction in wear under adverse conditions
• FDA Advisory Committee unanimously recommended
approval in August 2009
18. Self-monitoring of Blood Glucose (SMBG):
New Blue OneTouch® Ultra® Test Strips with
DoubleSure™ Technology
• Automatically double-checks each result for accuracy
• OneTouch® Ultra® Test Strips are glucose-specific and eliminate
the risk of falsely elevated results from other sugars
– Nearly 7 years of proven accuracy reinforces patient
and HCP confidence
• Leverages competitive advantage of one strip platform
for multiple meters
• Does not contain the GDH-PQQ enzyme
• U.S. launch in September 2009
19. Contact Lenses:
1•DAY ACUVUE® TruEye™
• World’s first daily disposable silicone hydrogel
• Sets the standard in healthy contact lens wear
for today’s non-stop eye
• Only contact lens to deliver on the four
dimensions of eye health:
– HEALTH YOU CAN SEE™
– HEALTH YOU CAN FEEL™
– PROTECTIVE HEALTH
– EVERYDAY HEALTH
• OUS Launches in 2008/09
• Planned U.S. Launch 2Q/3Q’10
20. Clinical Labs:
VITROS® 5600 and 3600 Systems
• Market penetration: New systems
double the markets served
• Menu expansion: Competitive
menu of clinical chemistry and
immunoassay tests
• New medical content:
Emerging assays
• FDA approved: 4Q08
21. Key Growth Strategies:
Launch Breakthrough New Products/Technologies
DES Electrophysiology Energy Biosurgicals Sedation
WW Market $4.8B $1.8B $1.5B $0.7B New Market
2009
2009-2014 2% 15% 15% 10% New Market
CAGR*
*Operational growth
Source: Combination of external and internal estimates
22. Drug-Eluting Stents (DES):
NEVO™ Sirolimus-Eluting Coronary Stent
• First and only drug-eluting stent utilizing RES Technology
• 75% bare metal upon insertion; fully bare metal in ~3 months
• Contains the drug Sirolimus – unmatched safety and
efficacy data
• Excellent deliverability
• Robust clinical strategy
• CE Mark Filing: 1Q 2010
• PMA Filing: 2012
23. Electrophysiology:
Atrial Fibrillation Ablation
• Advancing the use of ablation for treatment
of arrhythmias
• Focused on atrial fibrillation
– Most common sustained cardiac rhythm disturbance
– Prevalence of 22MM…only 88K treated with ablation
– Ablation fast-growing as second-line therapy
– Biosense Webster has first and only FDA approval to
treat Afib
– CARTO® 3 system launching OUS
24. Energy:
ENSEAL® + HARMONIC®
• Acquired SurgRX in 2008
• Expand leadership in “energy-based” surgical
instruments
• ENSEAL® and HARMONIC® are complementary
technologies
• ENSEAL® – Advanced bipolar device for large
vessel sealing
• HARMONIC® – Ultrasonic device for procedures
requiring multi-functionality
25. Biosurgicals:
Fibrin Pad
• Acquired Omrix Biopharmaceuticals
in 2008
• Advanced hemostat to address
bleeding in surgical settings
• Combines functions of mechanical
sealing and biological hemostasis
• BLA Submission: 2009
26. Sedation:
The SEDASYS® System
• First Computer-Assisted Personalized
Sedation System
• Integrates precise drug delivery and patient
monitoring
• For use by physician/nurse teams to deliver
minimal-to-moderate propofol sedation
• Targeting colonoscopy and EGD procedures –
16 million U.S. screening procedures per year*
• Favorable FDA advisory panel recommendation
in May 2009
*Internal Estimate
27. Key Growth Strategies:
Accelerate Growth in Emerging Markets
Market Size 2009-2014 CAGR
MD&D BRIC Market $6.0 Billion 15%
Brazil $1.7 Billion 11%
Russia $0.9 Billion 14%
India $0.8 Billion 18%
China $2.6 Billion 18%
*Data source: Internal Estimates and based on markets J&J competes in and is not reflective of the entire MD&D market; Constant Dollars
28. Key Growth Strategies:
Accelerate Growth in Emerging Markets
• Improve access, affordability,
education
– Market-appropriate products
– Partnerships with government
• Gain meaningful local market insights
– R&D Centers in China/India
– Manufacturing in Brazil/China/India
– Surgical Training Centers in all BRIC countries
– Johnson & Johnson Diabetes Institute in China
29. Key Growth Strategies:
Drive Operational Effectiveness and Efficiency
MD&D Operating Profit*, 2003 - 2008
8000
$8.0 35%
35%
Operating Profit ($ in Bn)
$6.0
6000 30%
30%
% to Sales
4000
$4.0 25%
25%
2000
$2.0 20%
20%
$00 15%
15%
2003 2004 2005 2006 2007 2008
Operating Profit $'s % to Sales
* Excludes IPR&D and other special items
30. Medical Devices & Diagnostics:
Well Positioned for Growth
• Strong history of delivering clinically-relevant solutions
• Favorable demographics and significant unmet needs globally
• Market-leading franchises with established growth platforms
and robust pipeline
• Broad technology, scientific, and regulatory expertise
• Global infrastructure, capabilities and networks
• Exceptional financial profile enables continued investment
in new markets, companies, and technologies
